Determination of immune status in dogs against CPV-2 by recombinant protein based latex agglutination test

Thomas, Jobin; Singh, Mithilesh; Goswami, T. K.; Glora, Philma; Chakravarti, Soumendu; Chander, Vikas; Upmanyu, Vikramaditya; Verma, Suman; Sharma, Chhavi; Mahendran, K.

doi:10.1016/j.biologicals.2017.06.009

Cited by 10 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This limitation is not considered important because titers in the high range indicate protective levels of immunity (17). As reported by Thomas et al (28), quite low and high HI titers may not have good correlations with any other serological test for the quantification of CPV specific antibodies. This was taken into account while analyzing our results, but in our case no differences were found when those values were eliminated.…”

Section: Discussionmentioning

confidence: 97%

Discrepancy Between In-clinic and Haemagglutination-Inhibition Tests in Detecting Maternally-Derived Antibodies Against Canine Parvovirus in Puppies

et al. 2021

View full text Add to dashboard Cite

Canine parvovirus (CPV) is one of the most common causes of mortality in puppies worldwide. Protection against CPV infection is based on vaccination, but maternally-derived antibodies (MDA) can interfere with vaccination. The aim of this study was to evaluate the applicability of an in-clinic ELISA test to assess the CPV MDA in unvaccinated puppies and CPV antibodies in bitches, comparing the results with the gold standard haemagglutination inhibition (HI) test. Serum samples of 136 unvaccinated puppies were tested, along with sera of 16 vaccinated bitches. Five unvaccinated puppies were retested after vaccination. Both assays showed that the 16 vaccinated bitches had protective antibody levels against CPV. Conversely, significant discrepancies were observed for the MDA titers in unvaccinated puppies. Protective MDA titers were observed in 91.9% puppies using HI and in 40.4% by the in-clinic ELISA test, and only the latter one showed a decrease of MDA titers and percentages of protected puppies after the first weeks of age. Vaccination of five puppies with high HI and low in-clinic ELISA MDA titers resulted in seroconversion. Our results confirm the reliability of the in-clinic ELISA test in determining protective antibodies against CPV in adult dogs. Our findings also suggest that the in-clinic ELISA test kit may also be a useful tool to detect and quantify CPV MDA, thus allowing prediction of the best time to vaccinate puppies and reduction of the rate of vaccination failures due to interference by maternally-derived antibodies.

show abstract

Section: Discussionmentioning

confidence: 97%

Discrepancy Between In-clinic and Haemagglutination-Inhibition Tests in Detecting Maternally-Derived Antibodies Against Canine Parvovirus in Puppies

et al. 2021

View full text Add to dashboard Cite

show abstract

“…That may be attributed to the vaccine failure. Thus, a good way to prevent this problem is to perform an antibody titer test, which the HI test is the standard gold test for detection of parvovirus antibodies [ 23 ]. Besides, the antibody testing could be performed at least 1 month after the last vaccination administered at 16 weeks or more and can be repeated every 3 years in the case of a positive result [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

The first evaluation of the effectiveness of canine vaccination schedule by two commercial vaccines in Iran

2022

View full text Add to dashboard Cite

Background Canine Parvovirus type 2 (CPV-2) is a member of the Parvoviridae family with a global distribution and causes pathogenicity in puppies aged from 6 weeks to 6 months. It should be noted that Maternally Derived Antibodies (MDA) have protection against CPV-2 in the first weeks of puppies’ life. However, MDA declines with age. The most important influential factor is timely vaccination against CPV-2. Methods In this study, 24 healthy 8-week-old terrier puppies were selected and divided into three identical groups based on a randomized, double-blind comparative trial. One of which was called the control group that was injected with the physiological serum. The second group was the group A that was vaccinated by the vaccine provided by Biocan DHPPi+L (Bioveta, Czech). The third group was group B that was vaccinated by the vaccine of Duramune Max 5 + LCI / GP (Fort Dodge Animal Health, USA) from 8 to 16 weeks of their life at every 4 weeks. Then serum samples were analyzed with HI and ELISA tests. Results The MDA titer was protective in some puppies until 18 weeks of age. Also, after the first vaccination, all puppies had a protective titer against CPV-2, and Duramune vaccine had seroconverted after the first injection and Biocan had seroconverted after the second injection. Conclusions It is recommended that to reduce the risk of vaccine failure: such as the MDA titer should be measured in puppies before designing a vaccination schedule.

show abstract

“…These recombinant truncated VP2 proteins are good candidates for ELISA or latex agglutination tests for CPV. Moreover, antigenic sites 6-7 have been reported as candidate antigenic sites to develop a subunit vaccine [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Expression of recombinant 35 kDa fragment of VP2 protein of canine parvovirus using Escherichia coli expression system

et al. 2021

View full text Add to dashboard Cite

Background and Aim: Canine parvovirus (CPV) is one of the most common viral infections in dogs, causing acute hemorrhagic gastroenteritis and high mortality. Vaccination effectively prevents CPV infection. However, the currently available CPV vaccines have concerns such as maternal immunity interference, shedding of virus vaccine, and false-positive result based on polymerase chain reaction after vaccination. A subunit vaccine can overcome these problems. This study aimed to express the recombinant 35 kDa fragment of the VP2 protein (consisting of epitopes 1-7) and the recombinant full-length VP2 protein (consisting of epitopes 1-10) and to study the ability of these two recombinant proteins to react with rabbit anti-CPV polyclonal antibodies. Materials and Methods: The full length and 35 kDa fragment of VP2 gene of CPV were cloned into the pBAD202 Directional TOPOTM expression vector and expressed in E. coli. The recombinant full-length and the recombinant 35 kDa fragment proteins of VP2 were analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting. Results: The recombinant full-length and the recombinant 35 kDa fragment VP2 genes were successfully cloned and expressed. The optimum concentrations of arabinose and induction time for the recombinant full-length and the recombinant 35 kDa fragment VP2 proteins were 0.2% for 6 h and 0.02% for 6 h, respectively. The recombinant full-length and the recombinant 35 kDa fragment VP2 protein molecular weights were approximately 81 and 51 kDa, respectively. The recombinant full-length and the recombinant 35 kDa fragment VP2 proteins specifically interacted with rabbit anti-CPV polyclonal antibodies. Conclusion: These results suggest that the recombinant 35 kDa fragment and the recombinant full-length VP2 proteins may be useful in developing a CPV diagnostic test or vaccine.

show abstract

Determination of immune status in dogs against CPV-2 by recombinant protein based latex agglutination test

Cited by 10 publications

References 33 publications

Discrepancy Between In-clinic and Haemagglutination-Inhibition Tests in Detecting Maternally-Derived Antibodies Against Canine Parvovirus in Puppies

Discrepancy Between In-clinic and Haemagglutination-Inhibition Tests in Detecting Maternally-Derived Antibodies Against Canine Parvovirus in Puppies

The first evaluation of the effectiveness of canine vaccination schedule by two commercial vaccines in Iran

Expression of recombinant 35 kDa fragment of VP2 protein of canine parvovirus using Escherichia coli expression system

Contact Info

Product

Resources

About